-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The U.S. Food and Drug Administration (FDA) has approved an IND application for the antigen-specific drug ANK-700 to treat multiple sclerosis (MS), Swiss biotech company Anokion SA announced recently.
plans to launch a multi-center Phase I clinical trial for MS patients by the end of the year.
is still a devastating disease," said Simon Cooper, chief medical officer of Anokion, a medical examiner.
, the benefits of available interventions are limited and often do not address the underlying mechanisms that lead to disease exacerbation.
an ANK-700 aims to re-integrate the immune system through a potential conversion method by utilizing natural immune tolerance pathways in the liver."
in preclinical models, Anokion has demonstrated that its effective liver-targeted technology-induced to-resistant T-cell mechanisms can effectively prevent or reduce the pathological response of MS.
In mouse models of MS, myelin-less protrusion glial glycosin (MOG) antigens targeting the liver induced pathological T cells to become unresponsive and missing, thus protecting them from disease attacks when they are to be tormented in active diseases.
.
